Hong Kong stock anomaly | Maiwei Biotechnology-B (02493.HK) rose more than 7% against the market trend. 9MW5211 injection clinical trial application approved by the National Medical Products Administration.

According to the Securities Times APP, Meiwu Biology-B (02493.HK) rose by more than 7% against the market trend. As of the time of publication, it had risen by 6.54% to HKD 23.78, with a trading volume of HKD 8.6025 million.